-
From RNA Nanoparticles to Translational Proof
2026-09-29
Nucleic acid delivery is advancing from cargo design toward programmable nanomedicine. This article examines how filamentous potato virus X nucleoprotein assemblies could support mRNA and circRNA delivery, why mechanistic validation must be paired with disciplined qPCR workflows, and where HotStart™ Universal Blue 2X Green qPCR Master Mix (with UDG) fits into a translational evidence strategy.
-
Hoechst 33342/PI Double Staining Kit: Practical Guide
2026-09-29
Use dual fluorescence to distinguish chromatin condensation from loss of plasma-membrane integrity in cultured cells. This workflow shows how to apply the assay to RCC drug-response studies, improve imaging consistency, and avoid confusing late apoptosis with primary necrosis.
-
Dronedarone (Multaq): Reading the KCa2 Evidence
2026-09-28
Dronedarone (Multaq) is best understood in KCa2-channel research through the limits as well as the findings of a key electrophysiology study. This article explains what the negative result means for assay design, mechanistic interpretation, and research use of the compound.
-
RAS/PI3K Mutations Sensitize Ovarian Cancer to PARP/NAMPT
2026-09-27
This study identifies RAS/PI3K pathway mutations as a candidate biomarker for sensitivity to combined PARP and NAMPT inhibition in epithelial ovarian cancer. Cell-line and mouse-model findings connect reduced NAD metabolism with oxidative stress, DNA damage, and apoptosis, motivating further investigation of this combination in biomarker-selected disease.
-
Cytochalasin B: A Workflow for Actin-Dependent Entry
2026-09-26
Use Cytochalasin B to test whether actin-dependent uptake and cell behavior contribute to an assay phenotype—not simply to suppress it. This guide translates a Spiroplasma–S2 cell study into a controlled workflow with dose-finding, viability checks, and practical troubleshooting.
-
ML-7 Hydrochloride in Cardiovascular Assays
2026-09-26
Use ML-7 hydrochloride to probe MLCK-dependent myosin light-chain phosphorylation in cardiac injury and endothelial-barrier experiments. A practical workflow pairs cautious dose finding with time-resolved pathway and functional readouts, while separating established cardiovascular evidence from exploratory assay ideas.
-
JXE-23 Triggers Protective Autophagy in HCC Cells
2026-09-25
A 2024 study reports that the fern-derived diterpene JXE-23 preferentially inhibited HepG2 hepatocellular carcinoma cells, induced G2/M arrest, and activated autophagy-associated responses. Because blocking autophagy further reduced cell viability, the findings suggest that this response may protect cells from JXE-23, although additional experiments are needed to define the mechanism and its relevance beyond the tested models.
-
gamma-Glu-Cys (γ-Glu-Cys): Assay Handling
2026-09-25
gamma-Glu-Cys (γ-Glu-Cys) is a defined intermediate for glutathione metabolism research, including glutathione synthetase assays and studies of phytochelcin formation. This guide covers practical solution preparation, handling, and controls; it is not a substitute for a validated assay protocol or evidence of biological activity in a particular model.
-
Leptin (116-130), amide, mouse: research workflow
2026-09-24
A practical guide to evaluating this mouse leptin fragment in metabolic and immunometabolic assays, with pilot conditions clearly separated from established product specifications. It also shows how to connect leptin-focused experiments to atrial inflammation research without assuming an unproven mechanism.
-
nor-Binaltorphimine Dihydrochloride in KOR Circuits
2026-09-24
nor-Binaltorphimine dihydrochloride is a selective κ-opioid receptor antagonist for testing how KOR signaling shapes pain circuits. This article connects a brain-to-spinal study of mechanical allodynia to practical decisions about experimental design, controls, and interpretation.
-
Gamma-Linolenic Acid: Assay Logic for Inflammation
2026-09-23
Gamma-linolenic acid (GLA) can serve as a defined lipid perturbation for inflammation, receptor, and cell-response studies. This guide develops an assay-decision framework that connects mechanism, formulation, cytotoxicity, and infection-control context without overstating the evidence.
-
CDK8/19 Inhibition in Osteoarthritis: Key Findings
2026-09-23
A 2026 Bone Research study identifies CDK8/19 inhibition as a multiprocess strategy for osteoarthritis, linking chondrocyte hypertrophy, inflammatory signaling, metabolism, matrix preservation, and endochondral ossification. Its integrated cell, human tissue, transcriptomic, and STR/Ort mouse experiments provide a useful framework for evaluating disease modification beyond cartilage lesion scoring alone.
-
(+)-JQ1 in AR-Heterogeneous Prostate Cancer
2026-09-22
Bromodomain Inhibitor, (+)-JQ1 can help dissect transcriptional dependencies in heterogeneous prostate cancer models. This article translates AR-state biology into phenotype-stratified assay design, controls, and interpretation rather than treating BET inhibition as a one-size-fits-all response.
-
Realgar CNS Toxicity: The OTC–Ornithine–ZBTB7A Axis
2026-09-21
A 2025 Advanced Science study identifies a liver–brain mechanism linking realgar-derived arsenic, hepatic OTC inhibition, ornithine accumulation, and ZBTB7A-mediated suppression of astrocyte glycolysis. Its integrated animal, cell, single-cell transcriptomic, metabolomic, behavioral, and histopathological analyses provide a mechanistic framework for studying arsenic-associated neurotoxicity and metabolic disruption.
-
Azithromycin and Roxithromycin as Senolytics
2026-09-21
Ozsvari et al. used a controlled fibroblast senescence model to identify azithromycin and roxithromycin as selective senolytic candidates, while the closely related erythromycin was inactive. Their combination of SRB viability testing, metabolic analysis, and real-time impedance measurements provides a practical framework for drug repurposing and senescent cell detection.